Medical Device Go-to-Market Strategy: From FDA Clearance to Commercial Adoption

FDA Clearance Is Not a Commercial Strategy

Getting 510(k) clearance or PMA approval is a regulatory milestone. It is not a commercial milestone. Between the day the FDA clears your device and the day a hospital actually purchases it, there is a gap that most device companies dramatically underestimate. That gap involves reimbursement codes, coverage policies, distribution agreements, clinical evidence packages, physician training programs, procurement committee presentations, and a sales organization that can navigate all of it.

The numbers tell the story. The global medical device market is projected to reach $595 billion in 2026, growing at a 5.6% compound annual growth rate. The US represents 46.4% of that market — the single largest opportunity for most device companies. But hospital operating margins run 2–5%, and every purchasing decision is filtered through the question: Will we get reimbursed for using this? Can we justify the clinical and economic value?

A device without a go-to-market (GTM) strategy is a device that stays on the shelf. This guide provides a comprehensive framework for building that strategy — from regulatory-commercial alignment through post-launch scaling.

The GTM Framework: Seven Components

A medical device go-to-market strategy has seven interdependent components. Weakness in any one undermines the others.

1. Regulatory-commercial alignment — your regulatory pathway determines your commercial timeline and evidence requirements
2. Reimbursement and coding strategy — codes, coverage, and payment before you sell a single unit
3. Target market and customer segmentation — which hospitals, which physicians, which procedures
4. Value proposition and clinical evidence — the clinical and economic case for adoption
5. Sales channel model — direct sales, distributor network, or hybrid
6. Pricing and contracting — how you price relative to alternatives and navigate GPO contracts
7. Launch execution — the 12–18 month timeline from pre-launch activities through commercial scaling

Component 1: Regulatory-Commercial Alignment

Your regulatory pathway is the foundation of your GTM strategy. It determines your timeline, your costs, your evidence base, and your competitive positioning.

Pathway Implications for GTM

A 510(k) device enters a market with existing predicate devices. Your GTM strategy must differentiate on features, clinical outcomes, or cost — not on the novelty of the regulatory pathway. A De Novo or PMA device has a stronger clinical evidence moat, but the longer timeline means your GTM planning must start earlier and your commercial team must be built to sustain a longer runway.

The Capital Reality

Your GTM strategy must align with your funding timeline:

A PMA-track device that cannot generate revenue for 5–7 years requires fundamentally different investor conversations and GTM timelines than a 510(k) device that could be on the market in 12 months.

Component 2: Reimbursement and Coding Strategy

Reimbursement is the gatekeeper to hospital adoption. If hospitals cannot get paid for using your device, they will not buy it. Reimbursement planning must begin 2–3 years before launch — not after FDA clearance.

The Three Reimbursement Questions

1. Is there a billing code? (CPT for procedures, HCPCS for devices/supplies, ICD-10 for diagnoses)
2. Is there a coverage policy? (NCD nationwide, LCD regionally, or commercial payer policies)
3. Is the payment adequate? (Does the DRG, APC, or fee schedule rate cover the device cost?)

If the answer to any of these is "no," you have reimbursement work to do before you can sell.

Reimbursement Planning Timeline

NTAP for Inpatient Devices

The New Technology Add-On Payment (NTAP) provides additional payment on top of the DRG rate for new devices that meet specific criteria. For FY 2026, NTAP payments include up to $2.3 million per case for certain gene therapies and up to $316,860 for CAR-T therapies. NTAP can add 50–65% of device cost to the DRG payment, making it a critical bridge for inpatient devices during their first two years on the market.

Component 3: Target Market and Customer Segmentation

Defining Your Ideal Customer Profile (ICP)

In medical devices, the ICP is not a single person — it is a buying committee. A typical hospital device purchase involves 5–12 stakeholders across clinical, technical, and administrative roles. Your GTM strategy must address all of them:

Hospital Segmentation

Not all hospitals are equal targets. Segment by:

• Procedure volume: Target hospitals that perform the highest volume of the relevant procedure
• Teaching status: Academic medical centers are early adopters; community hospitals follow
• System affiliation: Large health systems (HCA, CommonSpirit, Ascension) offer scale but require system-level contracts
• Geographic concentration: Start with a concentrated regional footprint for sales efficiency
• Reimbursement mix: Hospitals with favorable payer mix (more commercial insurance) are better targets for premium-priced devices

Component 4: Value Proposition and Clinical Evidence

Building the Clinical-Economic Case

Your value proposition must work at three levels:

1. Clinical: Does your device improve patient outcomes, reduce complications, or enable new procedures?
2. Operational: Does it reduce procedure time, simplify workflow, or require less training?
3. Economic: Does it lower total cost of care, reduce readmissions, or generate incremental revenue for the hospital?

The strongest value propositions address all three. A device that improves outcomes but costs more requires a health economics argument showing that the improved outcomes reduce downstream costs (fewer complications, shorter stays, reduced readmissions).

Evidence Requirements by Stakeholder

Key Opinion Leader (KOL) Strategy

KOL engagement should begin during clinical development, not at launch. Identify 5–10 physicians who are thought leaders in your target procedure area. Engage them as clinical advisors, involve them in early feasibility studies, and support their presentations at major conferences (MEDICA, MD&M, specialty society meetings). Their peer-reviewed publications and conference presentations become your most credible sales tool.

Component 5: Sales Channel Model

Three Models

Direct Sales Model Economics

A typical medical device sales representative costs $250K–$400K per year fully loaded (base + commission + benefits + expenses). A productive rep covers 30–50 accounts and generates $1.5M–$3M in annual revenue. At launch, expect 12–18 months before a new rep is fully productive.

Build your sales team in waves:

• Wave 1 (pre-launch): 3–5 reps in concentrated geography, focused on key accounts and clinical evaluations
• Wave 2 (6–12 months post-launch): Expand to 10–15 reps, adding territories based on early demand signals
• Wave 3 (12–24 months post-launch): Scale to 25–50+ reps, expanding to national coverage with regional sales managers

Distributor Selection Criteria

If using distributors, evaluate candidates on:

• Existing relationships with your target accounts
• Complementary (not competing) product portfolio
• Clinical selling capability (can they do in-service training?)
• Financial stability and credit terms
• Geographic coverage alignment with your target markets
• Willingness to carry inventory and manage logistics

Component 6: Pricing and Contracting

Pricing Framework

Medical device pricing is not a simple cost-plus exercise. It must account for:

• Reimbursement landscape: What is the procedure payment rate? Does the device cost fit within that rate?
• Competitive alternatives: What do predicate devices cost? What is your clinical differentiation worth?
• Value-based pricing: What is the total economic value to the hospital (improved outcomes + operational savings + revenue generation)?
• GPO and IDN contracts: Group purchasing organizations (Vizient, Premier, HealthTrust, Intalere) and integrated delivery networks negotiate volume-based discounts that can reduce your list price by 15–30%

Pricing by Launch Phase

GPO and IDN Strategy

Most US hospitals purchase through at least one GPO. Getting on GPO contracts is essential for scale but requires trade-offs:

• GPO contracts typically demand 10–25% below list price
• Contracts are multi-year (3–5 years), limiting pricing flexibility
• GPO compliance rates vary — some hospitals purchase 80%+ through their GPO, others much less
• A GPO contract is necessary but not sufficient — you still need to sell to individual hospitals within the GPO

Component 7: Launch Execution — The 18-Month Timeline

Phase 1: Pre-Launch (T-18 to T-6 months)

• Finalize reimbursement codes and coverage pathways
• Complete KOL clinical evaluations and collect case data
• Build sales team (hire and train first wave of reps)
• Develop sales enablement materials (clinical brochures, ROI calculator, competitive battle cards)
• Establish distribution partnerships
• File for GPO contract consideration
• Create product training and in-service programs
• Plan launch event (specialty conference or standalone event)

Phase 2: Launch (T-6 to T+3 months)

• Begin limited market release with 10–20 key accounts
• Support first clinical cases with on-site field support
• Collect early outcomes data and customer feedback
• Activate marketing campaigns (digital, conferences, peer-to-peer)
• Monitor reimbursement claims and address early denials
• Begin GPO contract negotiations

Phase 3: Growth (T+3 to T+12 months)

• Expand to full market release
• Scale sales team based on demand signals
• Publish early clinical results and case studies
• Secure GPO contracts for volume access
• Build reference sites for prospective customers
• Optimize pricing based on market feedback

Phase 4: Scale (T+12 to T+18 months)

• Achieve national coverage with sales team
• Expand indications or market segments
• Develop next-generation product roadmap based on user feedback
• Explore international expansion (EU MDR, UK CA marking)
• Build strategic partnerships for complementary products

Common GTM Mistakes

Mistake 1: Launching Without Reimbursement

The single most common GTM failure mode. A device hits the market, hospitals are interested, but there is no billing code or coverage policy. Sales stall. The company burns cash waiting for CMS to act. Start reimbursement planning 2–3 years before launch.

Mistake 2: Selling Only to Physicians

Physicians can request your device, but they do not approve purchases. Value analysis committees, CFOs, and supply chain managers hold the budget. Your GTM strategy must address every stakeholder in the buying committee with tailored evidence and messaging.

Mistake 3: Scaling Sales Too Fast

Hiring 30 reps at launch before you have proven clinical adoption, reimbursement workflows, and sales messaging is a recipe for cash burn. Start with 3–5 reps, prove the model, then scale.

Mistake 4: Ignoring the GPO Reality

If you are selling into US hospitals, you must engage GPOs. A product that is not on any GPO contract faces a structural pricing disadvantage against competitors that are.

Mistake 5: Underinvesting in Clinical Evidence

A single clinical trial is not enough. Your evidence base needs to grow continuously — peer-reviewed publications, case series, registry data, real-world evidence, health economics analyses. Budget for ongoing clinical evidence generation, not just the initial study.

International GTM: US-First Is the Default in 2026

For most device companies, the US should be the primary market at launch. The US represents 46.4% of the global medtech market. With the EU MDR Notified Body bottleneck — 28,489 applications but only 12,177 certificates issued as of early 2025 — European timelines are unpredictable and can add 12–24 months to the market entry timeline.

A practical international sequencing:

1. US first: Fastest path to revenue with the largest market
2. EU/UK second: Begin CE marking and UKCA processes in parallel with US commercialization; use US revenue to fund EU expansion
3. Key growth markets third: Japan, China, Australia, Canada — prioritize based on procedure volume and regulatory complexity
4. Emerging markets fourth: Brazil, India, South Korea, Middle East — pursue through distribution partnerships

Key Takeaways

1. FDA clearance is not a GTM strategy. The commercial path from clearance to adoption requires 12–18 months of preparation across reimbursement, sales, pricing, and evidence.
2. Start reimbursement planning 2–3 years before launch. Without codes, coverage, and adequate payment, hospitals will not buy your device.
3. Address the entire buying committee — physicians, VACs, procurement, CFOs, IT, and infection control each need different evidence and messaging.
4. Build your sales team in waves. Start with 3–5 reps in concentrated geography, prove the model, then scale.
5. GPO contracts are essential for US hospital sales. Factor 15–30% below list price into your pricing model from the beginning.
6. Clinical evidence is a continuous investment, not a one-time study. Budget for ongoing publications, registries, and real-world evidence.
7. Default to US-first in 2026 given the EU MDR bottleneck. Use early US revenue to fund international expansion.